Related Experiment Video
Updated: Jun 17, 2026
05:45
Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017
Improving seroreactivity-based detection of glioma.
Nicole Ludwig1, Andreas Keller, Sabrina Heisel
1Department of Human Genetics, Medical School, Saarland University, Building 60, Homburg/Saar, Germany. n.ludwig@mx.uni-saarland.de
Neoplasia (New York, N.Y.)
|December 19, 2009
Summary
Seroreactivity profiling shows promise for detecting glioma cancer using autoantibodies. This study identified specific antigens that can differentiate glioma patients from healthy individuals, aiding in early cancer diagnosis.
Area of Science:
- Oncology
- Immunology
- Biomarker Discovery
Background:
- Seroreactivity profiling is a minimally invasive technique for cancer detection.
- Previous studies suggested serum profiling's potential for glioma detection using limited immunogenic antigens.
Purpose of the Study:
- To evaluate the efficacy of autoantibody profiling in differentiating glioma patients from healthy controls.
- To identify specific antigens informative for glioma classification.
Main Methods:
- Screening of 57 glioma and 60 healthy sera against 1827 Escherichia coli expressed clones.
- Utilizing a linear support vector machine approach for classification.
- Calculating specificity, sensitivity, accuracy, and area under the receiver operator characteristic curve (AUC) for antigen ranking.
Main Results:
- Glioma sera were differentiated from healthy sera with 90.28% specificity, 87.31% sensitivity, and 88.84% accuracy.
- World Health Organization grade IV glioma sera showed higher differentiation accuracy (92.88%).
- 46 informative clones (16 in-frame) were identified for glioma vs. healthy classification, and 91 (26 in-frame) for glioblastoma vs. healthy classification.
Conclusions:
- Autoantibody signatures can effectively differentiate glioma patients from healthy individuals.
- Vimentin (VIM) emerged as a key antigen for glioma classification.
- This approach holds potential for glioma diagnosis and personalized immune-based therapy.
